Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 16;35(35 Pt A):4461-4464.
doi: 10.1016/j.vaccine.2017.04.085. Epub 2017 May 30.

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology

Sarah C Gilbert  1 , George M Warimwe  2
Affiliations
Review

Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology

Sarah C Gilbert et al. Vaccine. .

Abstract

Despite the fact that there had been multiple small outbreaks of Ebola Virus Disease, when a large outbreak occurred in 2014 there were no vaccines or drugs available for use. Clinical development of multiple candidate vaccines was then initiated in parallel with attempts to contain the outbreak but only one vaccine was eventually tested in a phase III trial. In order to be better prepared for future outbreaks of known human pathogens, platform technologies to accelerate vaccine development should be employed, allowing vaccine developers to take advantage of detailed knowledge of the vaccine platform and facilitating rapid progress to clinical trials and eventually to vaccine stockpiles. This review gives an example of one such vaccine platform, replication-deficient simian adenoviruses, and describes progress in human and livestock vaccine development for three outbreak pathogens, Ebola virus, Rift Valley Fever Virus and Middle East Respiratory Syndrome Coronavirus.

Keywords: Clinical trials; Outbreak pathogen; Simian adenoviral vector; Vaccination.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Herath S., Le Heron A., Colloca S., Patterson S., Tatoud R., Weber J. Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors. Vaccine. 2016;34:4378–4385. - PMC - PubMed
    1. Dicks M.D., Spencer A.J., Edwards N.J., Wadell G., Bojang K., Gilbert S.C. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE. 2012;7:e40385. - PMC - PubMed
    1. Feldmann H., Slenczka W., Klenk H.D. Emerging and reemerging of filoviruses. Arch Virol Suppl. 1996;11:77–100. - PubMed
    1. Stanley D.A., Honko A.N., Asiedu C., Trefry J.C., Lau-Kilby A.W., Johnson J.C. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–1129. - PubMed
    1. Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204(Suppl 3):S1075–S1081. - PMC - PubMed

MeSH terms

LinkOut - more resources